Roy Jakobs joins GSK (NYSE: GSK) Board as independent Non-Executive Director
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
GSK plc has appointed Roy Jakobs to its Board as an independent Non-Executive Director, effective 13 July 2026. He is currently Chief Executive Officer of Royal Philips, a global health technology company with 2025 sales of 17.8 billion EUR and 65,000 employees.
GSK’s Board determined that Jakobs meets independence criteria under the UK Corporate Governance Code. He will receive the standard annual Non-Executive Director fee of £122,258 and is required to build a holding of GSK shares equal to two times this fee, in line with the shareholder-approved Non-Executive Director remuneration policy.
Positive
- None.
Negative
- None.
Key Figures
Royal Philips 2025 sales: 17.8 billion EUR
Royal Philips employees: 65,000 employees
GSK NED annual fee: £122,258
+2 more
5 metrics
Royal Philips 2025 sales
17.8 billion EUR
Sales for Royal Philips in 2025
Royal Philips employees
65,000 employees
Royal Philips global workforce
GSK NED annual fee
£122,258
Standard annual fee for a GSK Non-Executive Director
Share ownership requirement
2x annual fee in GSK shares
Non-Executive Director shareholding guideline
GSK CEO appointment date
13 July 2026
Effective date Roy Jakobs joins GSK Board
Key Terms
Non-Executive Director, UK Corporate Governance Code, Nominations & Corporate Governance Committee, Non-Executive Director Remuneration policy, +1 more
5 terms
Non-Executive Director financial
"Roy Jakobs will join the Board of the Company as a Non-Executive Director"
A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.
UK Corporate Governance Code regulatory
"The Board has determined that Mr Jakobs is an independent Non-Executive Director in accordance with the UK Corporate Governance Code"
Nominations & Corporate Governance Committee financial
"The appointment of Mr Jakobs was made by the Board on the recommendation of the Nominations & Corporate Governance Committee"
Non-Executive Director Remuneration policy financial
"in accordance with the Company's shareholder approved Non-Executive Director Remuneration policy"
Voluntary Code of Conduct for Executive Search Firms regulatory
"an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms"
FAQ
What board change did GSK (GSK) announce in this Form 6-K?
GSK announced that Roy Jakobs will join its Board as an independent Non-Executive Director effective 13 July 2026. His appointment follows a skills-based search led by the Nominations & Corporate Governance Committee and supported by an external executive search firm.
Who is Roy Jakobs, the new GSK (GSK) Non-Executive Director?
Roy Jakobs is Chief Executive Officer of Royal Philips, a global health technology leader with 2025 sales of 17.8 billion EUR and 65,000 employees. He has held senior roles at Philips, Shell, and Elsevier and holds a Master’s in Business Administration.
How much will GSK (GSK) pay Roy Jakobs as a Non-Executive Director?
Roy Jakobs will receive GSK’s standard annual fee for a Non-Executive Director of £122,258. Under the company’s shareholder-approved Non-Executive Director remuneration policy, he must build a shareholding of GSK shares equal to two times this standard annual fee.
Is Roy Jakobs considered independent under GSK (GSK) governance standards?
GSK’s Board has determined that Roy Jakobs is an independent Non-Executive Director in accordance with the UK Corporate Governance Code. His appointment was recommended by the Nominations & Corporate Governance Committee after assessing his skills, experience, and capacity to fulfil the role.
Does Roy Jakobs have a service contract with GSK (GSK)?
Roy Jakobs does not have a service contract with GSK. Instead, he has a letter of appointment governing his role as a Non-Executive Director, which can be viewed by contacting the Company Secretary at GSK’s registered office.